Use App
Trending
News
Earnings
Newsletters
Advertise
All
DIA
0.16%
SPY
0.17%
QQQ
0.26%
Trending
RCAT
15.38%
DJT
1.01%
WLDS
76.25%
AAPL
0.10%
OPEN
29.52%
FNMA
5.04%
TWG
28.49%
SNPS
4.26%
LICN
12.35%
TC
7.25%
RCAT
15.38%
DJT
1.01%
WLDS
76.25%
AAPL
0.10%
OPEN
29.52%
FNMA
5.04%
TWG
28.49%
SNPS
4.26%
LICN
12.35%
TC
7.25%
home
Symbol
MASI
MASI
Masimo Corp
1,809
Loading...
Loading...
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
Should You Continue to Hold EXAS Stock in Your Portfolio?
Exact Sciences sees growth in Cologuard and Oncotype DX, but rising costs and tough competition weigh on EXAS shares.
Zacks
·
20h ago
Share to Feed
More News
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.
Zacks
·
21h ago
ILMN Stock to Gain From the Launch of Illumina Protein Prep Assay
The Illumina Protein Prep rollout boosts multiomics, strengthens disease insights and supports ILMN stock momentum.
Zacks
·
2d ago
Should You Hold Onto Globus Medical Stock in Your Portfolio for Now?
GMED rides strong musculoskeletal demand and new launches, but faces currency headwinds and fierce competition.
Zacks
·
7d ago
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Zacks
·
7d ago
New Strong Buy Stocks for September 4th
LRN, RL, ATRO, MASI and BYD have been added to the Zacks Rank #1 (Strong Buy) List on September 4, 2025.
Zacks
·
7d ago
QIAGEN Stock May Benefit From the US Clearance of QIAstat-Dx Rise
QGEN announces the launch of FDA-cleared QIAstat-Dx Rise, which may boost U.S. diagnostic access and testing capacity worldwide.
Zacks
·
8d ago
Is it Worth Retaining ResMed Stock in Your Portfolio Now?
RMD's Mask and Device sales fuel growth, but macro headwinds and fierce competition continue to challenge its performance.
Zacks
·
8d ago
Charles River Stock May Benefit From Joining EASYGEN Consortium
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Zacks
·
10d ago
Is it Apt to Hold Bio-Rad Stock in Your Portfolio Now?
BIO's strong ddPCR growth and solid diagnostics demand support its stock despite market pressures and stiff competition.
Zacks
·
10d ago
Latest MASI News
View
Advertisement.
Remove ads.
Advertisement.
Remove ads.
Advertisement.
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile